Our Capabilities-en

Our Capabilities-en (3)

Parliament endorsed the free trade and investment protection deals between EU and Singapore, serving as blueprint for further cooperation with Southeast Asia.

The US Food and Drug Administration’s Center for Biologics Evaluation and Research (CBER) on Wednesday released plans for what guidance is to be expected in 2019, including six final guidance documents related to gene therapies.

With almost 80 regenerative medicine advanced therapy (RMAT) designation requests in 2017 and 2018, it’s clear that the US Food and Drug Administration’s (FDA) Center for Biologics Evaluation and Research (CBER) has been busy with RMATs, though only on Friday did the agency finalize guidance from 2017 on the designation.